CoQ10 may interact with certain medications, causing side effects or making them less effective. Find out if you shouldn't ...

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death ELIQUIS, Compared to Standard of Care Warfarin, Significantly Reduced:Risk of stroke or ...

Conclusions In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and ...

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure ...

Eliquis is a prescription drug used to treat or help prevent certain kinds of blood clots. Discover drug interactions in depth, when to avoid Eliquis, and more.

In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...

The reduction in the primary efficacy end point of stroke or systemic embolism with apixaban was observed across a broad range of INR control in the warfarin-treated patients.

Apixaban is a cost-effective alternative to warfarin in warfarin-suitable candidates and also compares well with aspirin in patients who cannot take the vitamin K antagonist. The findings, derived ...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation ...

A lifetime on the newer agent was cost-effective within US "reasonable norms" but didn't cut overall costs much by improving outcomes, mostly because apixaban itself is far costlier than warfarin.

Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.